- Category
- Defining Matters
- Date
- Aug. 26, 2021
- Title
-
Kramer Levin Secures Win in Hatch-Waxman Lawsuit Involving Cancer Treatment
On Aug. 19, 2021, Kramer Levin obtained a significant win in a litigation under the Hatch-Waxman Act involving our client’s blockbuster treatment for B cell cancers. Following a 7-day bench trial, U.S. Chief District Judge Colm F. Connolly, U.S. District Court for the District of Delaware, issued a decision upholding all four patents asserted against the generic manufacturers. The court held that each of the patents were valid, rejecting numerous invalidity arguments put forward by the generic companies and precluding them from selling generic versions of our client’s cancer treatment until all the patents expire in 2036.
The decision can be found here. The case was also covered in Reuters, Law360 and Bloomberg.
Related People
-
-
Hannah Lee
-
- Partner
- Silicon Valley
- vcard
-
-
-
Marcus A. Colucci
-
- Special Counsel
- New York
- vcard
-
-
-
Christine Willgoos
-
- Special Counsel
- New York
- vcard
-
-
-
Cristina L. Martinez
-
- Associate
- New York
- vcard
-
-
-
Jonathan Pepin
-
- Associate
- New York
- vcard
-
-
-
Daniel Williams
-
- Associate
- Silicon Valley
- vcard
-
-
-
Khushbu Shah, Ph.D.
-
- Scientific Advisor
- New York
- vcard
-
